Description: Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900 and Parvysmelanotide (VLRX001), both alpha-melanocyte stimulating hormone analogue; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. It is also developing NEURACTHEL (ACTH), an adrenocorticotropic hormone to produce cortisol and enables the combat of stress and regulation of immune responses, maintenance of blood pressure, moderation of blood sugar, and regulation of metabolism. The company was incorporated in 1999 and is headquartered in Melbourne, Australia.
Home Page: www.clinuvel.com
535 Bourke Street
Melbourne,
VIC
3000
Australia
Phone:
61 3 9660 4900
Officers
| Name | Title |
|---|---|
| Dr. Philippe Jacques Wolgen M.B.A., M.D. | CEO, MD & Director |
| Dr. Dennis J. Wright BPharm, M.Sc., Ph.D. | Chief Scientific Officer |
| Mr. Peter Vaughan | Chief Financial Officer |
| Mr. Lachlan Hay | Chief Operations Officer |
| Mr. Malcolm Bull | Head of Australian Operations & Investor Relations |
| Dr. Rose Quadbeck-Diel | Senior Vice President of Regulatory Affairs |
| Dr. Azza Hamila | Head of Quality Assurance & Drug Safety |
| Ms. Claire Newstead-Sinclair C.A. | Company Secretary |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 17.2414 |
|---|---|
| Trailing PE: | 17.3256 |
| Price-to-Book MRQ: | 3.0151 |
| Price-to-Sales TTM: | 4.5496 |
| IPO Date: | |
| Fiscal Year End: | June |
| Full Time Employees: | 0 |